Document Detail


Adoption and implementation of medications in addiction treatment programs.
MedLine Citation:
PMID:  21359109     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Little is known about the extent to which medications are being implemented as routine care in addiction treatment programs. This research describes medication adoption and implementation within the privately funded treatment sector.
METHODS: Face-to-face interviews were conducted with 345 administrators of a nationally representative sample of privately funded substance treatment organizations in the United States.
RESULTS: Rates of adoption of addiction treatment medications in private sector programs were lower than the adoption of psychiatric medications. Even when analyses were restricted to programs with access to physicians, adoption of each addiction treatment medication had occurred in less than 50% of programs. Within adopting programs, implementation was highly variable. While about 70% of patients with co-occurring psychiatric diagnoses received psychiatric medications, rates of implementation of medication-assisted treatment for opioid dependence and alcohol use disorders were just 34.4% and 24.0%, respectively.
CONCLUSIONS: Although previous research has documented higher rates of medication adoption in privately funded treatment programs, this study revealed that both adoption and implementation of pharmacotherapies to treat addiction remains modest. Future research should examine the different types of barriers to implementation, such as physician decision-making, patient preferences, and system-level barriers stemming from financing and public policy.
Authors:
Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Related Documents :
21150479 - History and evidence regarding hydrostatic shock.
943579 - Prognosis for resolution of moderate, primary reflux in girls.
14556359 - Appropriate medical care for persons in detention.
21364439 - Eighth iquam consensus conference position statement: transatlantic innovations, april ...
21524259 - Pharmacological treatments for cocaine dependence: is there something new?
21253339 - Analysis of initial baseline clinical parameters and treatment strategy associated with...
22150919 - Brain death in islamic ethico-legal deliberation: challenges for applied islamic bioeth...
6130389 - Can readmissions to a geriatric medical unit be prevented?
11096729 - Migraine.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of addiction medicine     Volume:  5     ISSN:  1932-0620     ISO Abbreviation:  J Addict Med     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-07-19     Completed Date:  2011-09-06     Revised Date:  2014-09-22    
Medline Journal Info:
Nlm Unique ID:  101306759     Medline TA:  J Addict Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  21-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alcohol Deterrents / therapeutic use
Alcoholism / rehabilitation*
Comorbidity
Drug Utilization / statistics & numerical data
Health Plan Implementation / statistics & numerical data*
Health Services Accessibility / statistics & numerical data
Health Services Research
Humans
Mental Disorders / rehabilitation*
Narcotic Antagonists / therapeutic use
Narcotics / therapeutic use
Opioid-Related Disorders / rehabilitation*
Psychotropic Drugs / therapeutic use*
Substance Abuse Treatment Centers / statistics & numerical data*
United States
Grant Support
ID/Acronym/Agency:
F32 AA016872-03/AA/NIAAA NIH HHS; R01 AA015974/AA/NIAAA NIH HHS; R01 AA015974-02/AA/NIAAA NIH HHS; R01 DA013110/DA/NIDA NIH HHS; R01 DA013110-08/DA/NIDA NIH HHS; R37 DA013110/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
0/Alcohol Deterrents; 0/Narcotic Antagonists; 0/Narcotics; 0/Psychotropic Drugs
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Depressive symptoms and bodily pain: The role of physical disability and social stress.
Next Document:  Control of Nanospaces with Molecular Devices.